Your session is about to expire
← Back to Search
Dendritic Cell Vaccine for Brain Cancer
Study Summary
This trial is testing which combination of immunotherapy vaccines is most effective in patients with malignant glioma, a type of brain cancer. Dendritic cells, which present cell identifiers to the immune system, are isolated from the subject's blood and pulsed with tumor lysate, a combination that is hoped will stimulate the immune system to recognize and destroy the patient's brain tumor. The pulsed dendritic cells are then injected back into the patient, with or without adjuvant imiquimod or poly ICLC.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot or do not want to come back for needed follow-ups.I have a history of immune system problems that could worsen with immunotherapy.I am 18 or older and can understand the consent form.I currently have an active infection.I am not pregnant, breastfeeding, and I use approved birth control methods.I have cancer that is not under control and not in remission.My brain tumor is classified as Grade III or IV glioma.I had surgery at UCLA and agreed to donate my tumor for research.My surgery confirmed I have a high-grade malignant brain tumor.I can care for myself but may not be able to do active work.I have received an organ transplant.
- Group 1: Tumor-lysate pulsed DC vaccination +adjuvant polyICLC.
- Group 2: Tumor Lysate-pulsed DC vaccination
- Group 3: Tumor lysate-pulsed DC vaccination+0.2% resiquimod.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the sample size for this clinical trial?
"This particular study has completed recruitment and is no longer looking for patients. The trial was initially posted on October 8th, 2010, with the most recent update being on July 18th, 2022. If you are interested in other studies, there are 744 clinical trials currently underway for patients with glioma and 1 autologous tumor lysate-pulsed DC vaccination study that is actively recruiting participants."
Are patients still being enrolled in this research project?
"Unfortunately, this trial is no longer recruiting patients. The study was first posted on October 8th, 2010 and was updated for the last time on July 18th, 2022. However, there are still 744 trials searching for patients with glioma and 1 autologous tumor lysate-pulsed DC vaccination study that are currently open to enrolment."
Does age preclude patients from participating in this research?
"This trial requires that all participants be between 18-70 years old, as specified in the eligibility criteria."
Is it permissible to give patients autologous tumor lysate-pulsed DC vaccinations?
"Autologous tumor lysate-pulsed DC vaccination is a Phase 2 trial, which means that while there is some safety data supporting its use, efficacy has yet to be proven."
Are there other clinical trials that have used autologous tumor lysate-pulsed DC vaccination?
"Currently, there is 1 clinical trial testing autologous tumor lysate-pulsed DC vaccination. No trials have reached Phase 3 yet. Most of the locations for this study are in Los Angeles, California; however, there is 1 other site conducting these tests."
Are there any specific requirements for participants in this clinical trial?
"This trial is recruiting 60 participants, between the ages of 18 and 70 who have glioma. It is important that patients also meet the following criteria: Patients must have had surgical resection at UCLA (University of California, Los Angeles), for which a separate informed consent was signed for the collection of their tumor prior to surgery., Patients with newly diagnosed or recurrent glioma of WHO Grade III or IV {anaplastic astrocytoma (AA), anaplastic astro-oligodendroglioma (AO), or glioblastoma (GBM)} will be eligible for this protocol"
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger